NervGen Pharma (TSE:NGEN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
NervGen Pharma, a clinical-stage biotech company, is set to present at the Stifel 2024 Healthcare Conference, highlighting its innovative treatments for nervous system repair. The company’s lead molecule, NVG-291, is currently being tested for spinal cord injury, while a new candidate, NVG-300, is in preclinical evaluation for stroke and ALS.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
